Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016, Article ID 2473234, 8 pages
http://dx.doi.org/10.1155/2016/2473234
Clinical Study

A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy

1Department of Ophthalmology, The First People’s Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China
2Department of General Surgery, The First People’s Hospital of Yunnan Province, Yunnan 650032, China
3State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong 510062, China

Received 7 October 2015; Revised 5 January 2016; Accepted 10 February 2016

Academic Editor: Paolo Lanzetta

Copyright © 2016 Xiaochun Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Schrey, K. Krepler, and A. Wedrich, “Incidence of rhegmatogenous retinal detachment after vitrectomy in eyes of diabetic patients,” Retina, vol. 26, no. 2, pp. 149–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. V. S. Hershberger, J. J. Augsburger, R. K. Hutchins, L. A. Raymond, and S. Krug, “Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings,” Ophthalmology, vol. 111, no. 6, pp. 1215–1221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Shi and Y.-F. Huang, “Postvitrectomy diabetic vitreous hemorrhage in proliferative diabetic retinopathy,” Journal of Research in Medical Sciences, vol. 17, no. 9, pp. 865–871, 2012. View at Google Scholar · View at Scopus
  4. A. Blum, D. Socea, R. S. Ben-Shushan et al., “A decrease in VEGF and inflammatory markers is associated with diabetic proliferative retinopathy,” European Cytokine Network, vol. 23, no. 4, pp. 158–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Morera, R. González, H. Lamdan et al., “Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model,” Experimental Eye Research, vol. 122, pp. 102–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Wisniewska-Kruk, I. Klaassen, I. M. C. Vogels et al., “Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy,” Experimental Eye Research, vol. 122, pp. 123–131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Ferenchak, R. Duval, J. A. Cohen, and M. W. MacCumber, “Intravitreal bevacizumab for postoperative recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy,” Retina, vol. 34, no. 6, pp. 1177–1181, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Osaadon, X. J. Fagan, T. Lifshitz, and J. Levy, “A review of anti-VEGF agents for proliferative diabetic retinopathy,” Eye, vol. 28, no. 5, pp. 510–520, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Ahn, S. J. Woo, H. Chung, and K. H. Park, “The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy,” Ophthalmology, vol. 118, no. 11, pp. 2218–2226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Takahashi, “Vascular Endothelial Growth Factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy,” Biological and Pharmaceutical Bulletin, vol. 34, no. 12, pp. 1785–1788, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. C. Wykoff and S. M. Hariprasad, “Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T,” Ophthalmic Surgery, Lasers and Imaging Retina, vol. 46, no. 3, pp. 302–305, 2015. View at Publisher · View at Google Scholar
  12. K. Suto, Y. Yamazaki, T. Morita, and H. Mizuno, “Crystal structures of novel Vascular Endothelial Growth Factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1,” The Journal of Biological Chemistry, vol. 280, no. 3, pp. 2126–2131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Zhang, J. Zhang, M. Yan, H. Li, C. Yang, and D. Yu, “Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovascularization in monkeys,” Molecular Vision, vol. 14, pp. 37–49, 2008. View at Google Scholar · View at Scopus
  14. M. Zhang, J. Zhang, M. Yan et al., “A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration,” Ophthalmology, vol. 118, no. 4, pp. 672–678, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. L. P. Aiello, A. J. Brucker, S. Chang et al., “Evolving guidelines for intravitreous injections,” Retina, vol. 24, no. 5, pp. S3–S19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Cheng, X.-H. Liu, X. Shen, and Y.-S. Zhong, “Ahmed valve implantation for neovascular glaucoma after 23-gauge vitrectomy in eyes with proliferative diabetic retinopathy,” International Journal of Ophthalmology, vol. 6, no. 3, pp. 316–320, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-M. Yang, P.-T. Yeh, C.-H. Yang, and M.-S. Chen, “Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy,” American Journal of Ophthalmology, vol. 146, no. 2, pp. 211.e1–217.e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P.-T. Yeh, C.-M. Yang, Y.-C. Lin, M.-S. Chen, and C.-H. Yang, “Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy,” Retina, vol. 29, no. 6, pp. 768–774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. R. Ramezani, H. Ahmadieh, A. K. Ghaseminejad, S. Yazdani, and B. Golestan, “Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial,” British Journal of Ophthalmology, vol. 89, no. 8, pp. 1041–1044, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Wang, Y. Bai, W. Yu et al., “Anti-angiogenic effect of KH902 on retinal neovascularization,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 251, no. 9, pp. 2131–2139, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. G. A. Peyman, Vitreoretinal Surgical Techniques, Martin Dunitz, London, UK, 2001.
  22. D. F. Williams, J. M. Burke, and G. A. Williams, “Clearance of experimental vitreous hemorrhage after panretinal cryotherapy is related to macrophage influx,” Archives of Ophthalmology, vol. 108, no. 4, pp. 595–597, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Li, J. Hu, S. Du, Y. Chen, S. Wang, and Q. Wu, “ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes,” Molecular Vision, vol. 20, pp. 1109–1121, 2014. View at Google Scholar · View at Scopus
  24. M. Saint-Geniez, A. S. R. Maharaj, T. E. Walshe et al., “Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors,” PLoS ONE, vol. 3, no. 11, Article ID e3554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Li, N. Lei, M. Zhang, Y. Li, H. Xiao, and X. Hao, “Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit,” Experimental Eye Research, vol. 97, no. 1, pp. 154–159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. K. O. Chu, D. T. L. Liu, K. P. Chan et al., “Quantification and structure elucidation of in vivo bevacizumab modification in rabbit vitreous humor after intravitreal injection,” Molecular Pharmaceutics, vol. 9, no. 12, pp. 3422–3433, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. C. I. Sinapis, J. G. Routsias, A. I. Sinapis et al., “Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits,” Clinical Ophthalmology, vol. 5, no. 1, pp. 697–704, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. T. U. Krohne, N. Eter, F. G. Holz, and C. H. Meyer, “Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans,” American Journal of Ophthalmology, vol. 146, no. 4, pp. 508–512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. U. Krohne, Z. Liu, F. G. Holz, and C. H. Meyer, “Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans,” American Journal of Ophthalmology, vol. 154, no. 4, pp. 682–686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. C. H. Meyer, T. U. Krohne, and F. G. Holz, “Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans,” Retina, vol. 31, no. 9, pp. 1877–1884, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. T. U. Krohne, P. S. Muether, N. K. Stratmann et al., “Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors,” Retina, vol. 35, no. 1, pp. 69–74, 2015. View at Publisher · View at Google Scholar · View at Scopus